Chemical industry – Page 72
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
OM Group to be sold and split
Apollo Global Management will buy the firm for $1bn, then sell electronic materials business to Platform Specialty Products
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
Business
DuPont fined over fatal leak
Company lacked proper safety procedures to prevent deaths of four workers in methyl mercaptan leak
-
Business
Endo to buy Par as generics consolidation continues
$8bn deal follows trend as drugmakers aim for economies of scale
-
Business
Canada sets climate target
Canada aims to cut greenhouse gas emissions from energy-intensive sectors by 30% from 2005 levels by 2030
-
Business
GSK commits to HIV research
Firm will partner with US university and cancels plan to sell its share of ViiV Healthcare joint venture
-
Business
Judge refuses Freedom Industries’ bankruptcy plan
Court says $6.7m proposal from the company responsible for huge West Virginia chemical spill is inadequate
-
Business$13.8bn Danaher bid wins Pall auction
Mega-merger follows consolidation trend in lab equipment supply sector, but analysts suggest this is yet to impact pricing competition
-
Business
DuPont overcomes investor challenge
Shareholders decline to elect activist board nominees in a show of support for the current management’s strategy
-
BusinessTrade agreement could limit access to medicines
If approved in its leaked form, the Trans-Pacific Partnership would pose barriers for generic drugs to enter the market and keep drug prices high, warns the Foundation for Aids Research
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
Business
FDA accused of violating drug company’s freedom of speech
Amarin says the regulator is stopping it from giving ‘truthful, not misleading’ information to doctors about its fatty acid drug
-
Business
Alexion to buy Synageva for rare disease drugs
$8.4bn deal gives firm access to enzyme drug currently under review with US and EU regulators
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Zoetis to sell or close 10 plants in cost-cutting drive
Animal health firm will slash product portfolio in a bid to save $300m annually
-
BusinessKolon and Dupont settle trade secrets case
Korean firm admits stealing Kevlar technology and will pay $360m in fines and restitution